ReviewFrontiers in cellular neuroscience2026
From metabolism to mood regulation: astrocytes as a driver of depression.
Review in Frontiers in cellular neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Astrocytes are increasingly recognized as active regulators of mood and cognition, extending far beyond their classical supportive roles. In major depressive disorder, converging evidence from postmortem analyses, magnetic resonance spectroscopy (MRS), and animal stress models points toward the possibility of astrocytic abnormalities, including reduced density, impaired glutamate-glutamine cycling, and altered mitochondrial function. However, the causal contribution of these alterations remains insufficiently defined. This review aims to summarize experimental studies employing both loss- and gain-of-function approaches to directly probe the involvement of astrocytes in depression. We first introduce which inhibited astrocytic functions induce depressive-like behaviors, and then explore how enhancing these astrocytic functions-through overexpression and pharmacological manipulation methods-rescues stress-induced depression phenotypes. We further connect astrocyte alterations with circuit-level dysfunctions and behavioral outcomes, such as impaired prefrontal-amygdala regulation and reduced mesolimbic reward responses. Finally, we discuss therapeutic opportunities including astrocyte-targeting pharmacological strategies and MRS-based biomarkers. By integrating mechanistic evidence with translational perspectives, this review positions astrocyte metabolism as a promising frontier for antidepressant development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.